Celltrion stock reacts to Remsima price cut and strong Q2 growth

Published on 09/18/2026 at 14:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Celltrion stock faces health insurance price cuts for key autoimmune drug Remsima as of September 1, 2026, while Q2 2026 revenue rose 45.0 percent year on year. Investors weigh Japan market share gains against margin pressure from lower drug prices.

Celltrion, KR7068270008, Illustration mit AI erstellt.

Celltrion stock (ISIN KR7068270008) is trading under the shadow of newly lowered health insurance prices for its flagship autoimmune drug Remsima as of September 1, 2026, even as the company reported strong double digit revenue growth in the second quarter of 2026. For investors, the tension between volume growth and pricing pressure is key.

Drug price cuts hit Remsima from September 2026

On September 18, 2026, South Korea's National Health Insurance Service confirmed that it had completed negotiations to cut prices on 80 high usage prescription drugs under its 2026 price volume program, including Celltrion's Remsima intravenous and Remsima subcutaneous formulations.Asiae The price cuts, effective from September 1, 2026, average 4.6 percent across the 80 products and are expected to save KRW 33.9 billion in health insurance spending in 2026.Seoul Economic Daily

The inclusion of both Remsima IV and Remsima SC in the price reduction list means Celltrion faces lower reimbursed prices on a core biologic franchise in its home market, even as global demand for infliximab biosimilars continues to expand.Asiae For shareholders, the central question is whether higher volumes and international expansion can offset the margin pressure from the domestic price cuts.

Q2 2026 figures show strong top line momentum

Despite the new pricing headwinds, Celltrion entered the second half of 2026 with solid operational momentum. According to data compiled by Korean stock portal ATS View for the second quarter of 2026, Celltrion generated revenue of KRW 1.39 trillion in Q2 2026, up 45.0 percent compared with the same quarter a year earlier.ATS View This strong year on year increase underscores the continued growth of its biologics portfolio, led by Remsima and other oncology and autoimmune products.

Operating profit also expanded sharply. In Q2 2026, Celltrion reported operating profit of KRW 451.8 billion, corresponding to an operating margin of 32.4 percent for the quarter.ATS View The combination of 45.0 percent revenue growth and a margin above 30 percent illustrates that, ahead of the September 2026 price cuts, Celltrion was converting much of its top line expansion into bottom line earnings.

Q2 2026 also saw the company step up shareholder returns. According to ATS View, a company disclosure on September 16, 2026 confirmed that Celltrion had resolved to cancel approximately 540,000 shares of treasury stock, part of a broader share cancellation program worth KRW 2,000 billion this year.ATS View For context, the company earlier flagged a KRW 1,000 billion tranche of share cancellation as a way of returning about one third of its net profit to shareholders.ATS View

Japan market share gains highlight global strength

At the same time, Celltrion is strengthening its position in key overseas markets. As reported on September 18, 2026, Remsima has become the top infliximab product in Japan by market share roughly eleven years after its launch in that country.Nate News Based on data from pharmaceutical market research firm IQVIA, Remsima captured a 48 percent share of the Japanese infliximab market in July 2026, surpassing the originator product for the first time since its April 2015 launch.News1

Remsima now joins Celltrion's cancer drugs Herzuma and Vegzelma as number one products by market share in Japan, giving the company three leading biologics franchises in that market.Nate News Looking ahead, Celltrion plans to introduce Remsima SC in Japan in 2027, which could further expand its share of the autoimmune disease segment if the subcutaneous formulation is well received.Nate News

Stock performance and investor perspective

Recent trading data show that Celltrion shares are experiencing volatility around these mixed signals. A Korean market data briefing on September 18, 2026 noted that Celltrion was among the large cap names that finished the session lower, even as other technology and semiconductor stocks ended the day higher.Twig24 Another opening snapshot on the same date highlighted Celltrion rising about 0.58 percent in early trading as the KOSPI index and several blue chip names moved higher, underlining the intraday swings in sentiment.TokenPost

Against this backdrop, investors in Celltrion stock must balance several factors. On the positive side, Q2 2026 revenue growth of 45.0 percent to KRW 1.39 trillion and an operating margin of 32.4 percent show a business with strong scale and profitability.ATS View Shareholder friendly policies, including treasury share cancellations totaling around KRW 2,000 billion over the year and a commitment to return roughly one third of net profit, further underpin the equity story.ATS View

On the risk side, however, the average 4.6 percent price reduction on Remsima IV and SC as of September 1, 2026 directly compresses reimbursement levels in the domestic market.Seoul Economic Daily While Japan's 48 percent infliximab market share in July 2026 illustrates robust overseas demand, the domestic price cuts show that payers are actively pushing to contain biologics costs.News1 The medium term path of Celltrion stock will likely depend on whether strong international growth, upcoming launches such as Remsima SC in Japan and continued shareholder returns can offset the earnings drag from lower domestic prices.

Celltrion stock price snapshot

As of the latest completed trading session covered by Korean market summaries on September 18, 2026, Celltrion shares are listed on the Korea Exchange (KOSPI) under the ticker 068270 and have recently traded with modest percentage moves around broader index swings.TokenPost Specific intraday prices and volumes vary over the session, but the shares remain sensitive to news on drug pricing, overseas market share and shareholder return actions.